Therapeutic potential of protein and adjuvant vaccinations on tumour growth

C. M. Gérard; N. Baudson; K. Kraemer; C. Bruck; N. Garçon; Y. Paterson; Z. K. Pan; D. Pardoll

doi:10.1016/S0264-410X(00)00486-2

Therapeutic potential of protein and adjuvant vaccinations on tumour growth

C. M. Gérard, N. Baudson, K. Kraemer, C. Bruck, N. Garçon, Y. Paterson, Z. K. Pan, D. Pardoll

School of Medicine

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Over 90% of cervical cancers are associated with HPV infection, the commonest being the HPV-16 subtype. Two early viral genes, E6 and 7, play major roles in the development and maintenance of the malignant phenotype. The vaccine potential of a recombinant HPV16 E7 protein was examined in two murine models of E7-expressing tumours. Formulations including the immunostimulants MPL and QS21 induced therapeutically active immune responses leading to regression of pre-established TC1 tumour lesions, associated with induction of IgG antibodies, lymphoproliferation and CTL. Our data provide a clear incentive to investigate the clinical application of this approach in cancer immunotherapy.

Original language	English (US)
Pages (from-to)	2583-2589
Number of pages	7
Journal	Vaccine
Volume	19
Issue number	17-19
DOIs	https://doi.org/10.1016/S0264-410X(00)00486-2
State	Published - Mar 21 2001

Keywords

Adjuvants
Cancer immunotherapy
HPV E7 protein

ASJC Scopus subject areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

Access to Document

10.1016/S0264-410X(00)00486-2

Cite this

@article{d21a4636552a4dc5ab554642767547fd,

title = "Therapeutic potential of protein and adjuvant vaccinations on tumour growth",

abstract = "Over 90% of cervical cancers are associated with HPV infection, the commonest being the HPV-16 subtype. Two early viral genes, E6 and 7, play major roles in the development and maintenance of the malignant phenotype. The vaccine potential of a recombinant HPV16 E7 protein was examined in two murine models of E7-expressing tumours. Formulations including the immunostimulants MPL and QS21 induced therapeutically active immune responses leading to regression of pre-established TC1 tumour lesions, associated with induction of IgG antibodies, lymphoproliferation and CTL. Our data provide a clear incentive to investigate the clinical application of this approach in cancer immunotherapy.",

keywords = "Adjuvants, Cancer immunotherapy, HPV E7 protein",

author = "G{\'e}rard, {C. M.} and N. Baudson and K. Kraemer and C. Bruck and N. Gar{\c c}on and Y. Paterson and Pan, {Z. K.} and D. Pardoll",

year = "2001",

month = mar,

day = "21",

doi = "10.1016/S0264-410X(00)00486-2",

language = "English (US)",

volume = "19",

pages = "2583--2589",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "17-19",

}

TY - JOUR

T1 - Therapeutic potential of protein and adjuvant vaccinations on tumour growth

AU - Gérard, C. M.

AU - Baudson, N.

AU - Kraemer, K.

AU - Bruck, C.

AU - Garçon, N.

AU - Paterson, Y.

AU - Pan, Z. K.

AU - Pardoll, D.

PY - 2001/3/21

Y1 - 2001/3/21

N2 - Over 90% of cervical cancers are associated with HPV infection, the commonest being the HPV-16 subtype. Two early viral genes, E6 and 7, play major roles in the development and maintenance of the malignant phenotype. The vaccine potential of a recombinant HPV16 E7 protein was examined in two murine models of E7-expressing tumours. Formulations including the immunostimulants MPL and QS21 induced therapeutically active immune responses leading to regression of pre-established TC1 tumour lesions, associated with induction of IgG antibodies, lymphoproliferation and CTL. Our data provide a clear incentive to investigate the clinical application of this approach in cancer immunotherapy.

AB - Over 90% of cervical cancers are associated with HPV infection, the commonest being the HPV-16 subtype. Two early viral genes, E6 and 7, play major roles in the development and maintenance of the malignant phenotype. The vaccine potential of a recombinant HPV16 E7 protein was examined in two murine models of E7-expressing tumours. Formulations including the immunostimulants MPL and QS21 induced therapeutically active immune responses leading to regression of pre-established TC1 tumour lesions, associated with induction of IgG antibodies, lymphoproliferation and CTL. Our data provide a clear incentive to investigate the clinical application of this approach in cancer immunotherapy.

KW - Adjuvants

KW - Cancer immunotherapy

KW - HPV E7 protein

UR - http://www.scopus.com/inward/record.url?scp=0035925670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035925670&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(00)00486-2

DO - 10.1016/S0264-410X(00)00486-2

M3 - Article

C2 - 11257396

AN - SCOPUS:0035925670

SN - 0264-410X

VL - 19

SP - 2583

EP - 2589

JO - Vaccine

JF - Vaccine

IS - 17-19

ER -

Therapeutic potential of protein and adjuvant vaccinations on tumour growth

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this